Related Experiment Video

Updated: Jun 12, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy

Christopher A Crout1, Liang-Piu Koh, Jon P Gockerman

  • 1Duke University Medical Center, Department of Medicine, Division of Oncology and Stem Cell Transplantation, Adult Bone Marrow Transplantation Program, Durham, NC, USA.

Cancer Investigation
|June 5, 2010
PubMed

Insights

Mantle cell lymphoma often shows genetic changes causing drug resistance. Intense chemotherapy showed initial responses but few lasting remissions, highlighting the need for novel treatment strategies.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma.
  • Drug resistance is a significant challenge in MCL treatment.
  • Glutathione S-transferases (GSTs) are key drug-resistance proteins.

Purpose of the Study:

  • To investigate the prevalence of genetic polymorphisms and gene expression of GSTs in MCL.
  • To understand the role of GSTs in chemotherapy failure in MCL.
  • To evaluate the efficacy of dose-dense, intense chemotherapy in overcoming drug resistance in MCL.

Main Methods:

  • Analysis of genetic polymorphisms in GST genes.
  • Measurement of GST gene expression levels.
  • Clinical evaluation of patients receiving dose-dense, intense chemotherapy.

Main Results:

  • A high frequency of genetic alterations conferring drug resistance was observed in MCL.
  • Intense chemotherapy regimens led to high initial response rates.
  • Durable remissions were limited, suggesting resistance mechanisms were not fully overcome.

Conclusions:

  • Genetic alterations in GSTs contribute significantly to chemotherapy resistance in MCL.
  • Standard chemotherapy, even intensified, may not achieve durable remissions due to resistance.
  • Investigating non-traditional chemotherapy options is crucial for improving MCL outcomes.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...